Seismic waves running through the #diabetes community today as rumors and speculation fly after Bloomberg reports that $DXCM and $PODD are in potential merger talks. Let's take a step back and look at this logically. (a 🧵) finance.yahoo.com/news/dexcom-ta… On the surface, this makes at least *some* logical sense. While the clinical data on the G7 shown at ATTD this year looks to be basically best-in-class, Abbott's FSL3 is a serious competitor as a full iCGM, and I'd expect @dexcom to make moves to hinder their entry...

14-day comparisons! Photo 1 (2/27-3/12) is the baseline. #2 (3/13-3/26) is full #closedloop with Humalog and #DynamicISF. #3 (4/20-5/03) is full closed loop w/a 50/50 Humalog/Lyumjev mix. Best results with faster insulin. TIR gains are minimal (starting from a high baseline). 1/? What jumps out at me are the reductions in variability. Also, the Lyumjev/Humalog results probably would have been even higher TIR and less variable had the restaurant not messed up last night, delivering basically a whole chicken rather than the 2 chicken burritos I ordered. 2/?

Since people are going gaga over the Vertex Pharma T1D stem-cell announcement yesterday, here's a quick review of where we are, and how we got here: 🧵👇 Islet transplants have been happening for more than two decades: pubmed.ncbi.nlm.nih.gov/10911004/